You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/72360
Full metadata record
DC FieldValueLanguage
dc.contributor.authordos Santos, Jean Leandro-
dc.contributor.authorLanaro, Carolina-
dc.contributor.authorChin, Chung Man-
dc.date.accessioned2014-05-27T11:25:50Z-
dc.date.accessioned2016-10-25T18:33:45Z-
dc.date.available2014-05-27T11:25:50Z-
dc.date.available2016-10-25T18:33:45Z-
dc.date.issued2011-04-01-
dc.identifierhttp://dx.doi.org/10.2174/187152511796196506-
dc.identifier.citationCardiovascular and Hematological Agents in Medicinal Chemistry, v. 9, n. 2, p. 113-127, 2011.-
dc.identifier.issn1871-5257-
dc.identifier.issn1875-6182-
dc.identifier.urihttp://hdl.handle.net/11449/72360-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/72360-
dc.description.abstractSickle Cell Disease (SCD) is one of the most prevalent hematological diseases in the world. Despite the immense progress in molecular knowledge about SCD in last years few therapeutical sources are currently available. Nowadays the treatment is performed mainly with drugs such as hydroxyurea or other fetal hemoglobin inducers and chelating agents. This review summarizes current knowledge about the treatment and the advancements in drug design in order to discover more effective and safe drugs. Patient monitoring methods in SCD are also discussed. © 2011 Bentham Science Publishers Ltd.en
dc.format.extent113-127-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectChelating agents-
dc.subjectDrug discovery-
dc.subjectFetal hemoglobin-
dc.subjectGardos channel-
dc.subjectGene therapy-
dc.subjectHemoglobin modifiers-
dc.subjectHydroxyurea-
dc.subjectNew drugs-
dc.subjectNitric oxide-
dc.subjectPatient monitoring-
dc.subjectPoloxamer 188-
dc.subjectSickle cell-
dc.subjectSickle cell treatment-
dc.subjectStem cell transplant-
dc.subject5 aza 2' deoxycytidine-
dc.subject5 hydroxymethylfurfural-
dc.subjectaldehyde derivative-
dc.subjectantifungal agent-
dc.subjectantiinfective agent-
dc.subjectarginase-
dc.subjectcalcium-
dc.subjectciklavit-
dc.subjectclotrimazole-
dc.subjectdeferasirox-
dc.subjectdeferoxamine-
dc.subjectdeferoxamine mesylate-
dc.subjectendothelial nitric oxide synthase-
dc.subjectglutamic acid-
dc.subjecthemoglobin-
dc.subjecthemoglobin S-
dc.subjecthydroxyurea-
dc.subjectiron chelating agent-
dc.subjectNiprisan-
dc.subjectnitric oxide-
dc.subjectns 1652-
dc.subjectns 3623-
dc.subjectopiate-
dc.subjectorphan drug-
dc.subjectplant medicinal product-
dc.subjectpoloxamer-
dc.subjectpyrimidine antagonist-
dc.subjectunclassified drug-
dc.subjectunindexed drug-
dc.subjectvaline-
dc.subjectvanillin-
dc.subjectvitamin D-
dc.subjectabsence of side effects-
dc.subjectacute chest syndrome-
dc.subjectacute toxicity-
dc.subjectaplastic crisis-
dc.subjectbioavailability-
dc.subjectblood transfusion-
dc.subjectbone density-
dc.subjectbone marrow suppression-
dc.subjectcancer development-
dc.subjectcell cycle G1 phase-
dc.subjectcell cycle S phase-
dc.subjectdeoxygenation-
dc.subjectdrug bioavailability-
dc.subjectdrug cost-
dc.subjectdrug design-
dc.subjectdrug dose increase-
dc.subjectdrug marketing-
dc.subjectdrug megadose-
dc.subjectdrug safety-
dc.subjectenergy metabolism-
dc.subjecterythrocyte shape-
dc.subjecterythrocyte structure-
dc.subjecterythrocyte transfusion-
dc.subjectgastrointestinal symptom-
dc.subjectgrowth retardation-
dc.subjecthealth education-
dc.subjecthemolysis-
dc.subjecthuman-
dc.subjecthyperpigmentation-
dc.subjectimmunization-
dc.subjectin vitro study-
dc.subjectin vivo study-
dc.subjectinfection sensitivity-
dc.subjectinflammation-
dc.subjectinjection site infection-
dc.subjectinjection site inflammation-
dc.subjectiron overload-
dc.subjectleg ulcer-
dc.subjectmedicinal plant-
dc.subjectmulticenter study (topic)-
dc.subjectneglected disease-
dc.subjectosteomalacia-
dc.subjectosteoporosis-
dc.subjectoxygen transport-
dc.subjectoxygenation-
dc.subjectpain-
dc.subjectpatient compliance-
dc.subjectpatient monitoring-
dc.subjectphase 2 clinical trial (topic)-
dc.subjectplant seed-
dc.subjectpriapism-
dc.subjectquality of life-
dc.subjectrandomized controlled trial (topic)-
dc.subjectrash-
dc.subjectshunting-
dc.subjectsickle cell anemia-
dc.subjectside effect-
dc.subjectsupplementation-
dc.subjectsurvival-
dc.subjecttreatment duration-
dc.subjectulcerative lesion-
dc.subjectvitamin supplementation-
dc.subjectAnemia, Sickle Cell-
dc.subjectAnimals-
dc.subjectAntisickling Agents-
dc.subjectChelating Agents-
dc.subjectDrug Discovery-
dc.subjectErythrocytes-
dc.subjectHemoglobins-
dc.subjectHemorheology-
dc.subjectHumans-
dc.subjectNitric Oxide-
dc.subjectPlant Preparations-
dc.titleAdvances in sickle cell disease treatment: From drug discovery until the patient monitoringen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)-
dc.description.affiliationLapdesf-Laboratório de Pesquisa e Desenvolvimento de Fármacos Departamento de Fármacos e Medicamentos Universidade Estadual Paulista-UNESP, Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP-
dc.description.affiliationThe Haematology and Haemotherapy Centre State University of Campinas-UNICAMP, Hemocentro, Rua Carlos Chagas, 480, Barão Geraldo, 13083-970, Campinas, SP-
dc.description.affiliationUnespLapdesf-Laboratório de Pesquisa e Desenvolvimento de Fármacos Departamento de Fármacos e Medicamentos Universidade Estadual Paulista-UNESP, Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP-
dc.identifier.doi10.2174/187152511796196506-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofCardiovascular and Hematological Agents in Medicinal Chemistry-
dc.identifier.scopus2-s2.0-79957964590-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
Show simple item record Show full item record   View Statistics
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.